Vonjo (pacritinib) / SOBI, CTI BioPharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vonjo (pacritinib) / SOBI
NCT00741871: A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Completed
1
35
US
SB1518
S*BIO
Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
10/11
10/11
NCT02803762: Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

Completed
1
6
Europe
Pacritinib
CTI BioPharma, QPS-Qualitix
Healthy
10/14
10/14
NCT02807051: To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

Completed
1
20
US
Pacritinib, Pacritinib 100mg, Clarithromycin, Clarithromycin 500mg, Pacritinib and Clarithromycin, Pacritinib 100mg and Clarithromycin 500mg
CTI BioPharma, Covance
Drug Interaction Study
10/14
10/14
NCT02807207: To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Completed
1
42
US
A: pacritinib, A: pacritinib 400mg, B: Placebo, C: moxifloxacin, C: moxifloxacin 400mg
CTI BioPharma, Covance
Healthy Subjects
12/14
12/14
NCT02807116: Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Completed
1
18
US
Pacritinib, PAC400 mg, Rifampin, Rifampin600 mg, Pacritinib and Rifampin, PAC400 mg and rifampin 600mg
CTI BioPharma, Covance
Healthy Subjects
02/15
02/15
NCT02808455: Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

Completed
1
12
US
(Treatment A), Pacritinib 400 mg Capsule, (Treatment B), Pacritinib 80 mg Solution
CTI BioPharma, Covance
Healthy Subjects
03/15
03/15
NCT02765724: Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

Completed
1
28
Europe, RoW
Pacritinib, Pacritinib 400mg capsule
CTI BioPharma, SGS S.A.
Myelofibrosis
06/15
06/15
NCT02807077: PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Completed
1
40
Europe, RoW
Pacritinib
CTI BioPharma, SGS S.A.
Myelofibrosis
07/15
07/15
NCT02823171: To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Completed
1
28
US
Treatment A: 400 mg Pacritinib P3CT, PAC400mg P3CT, Treatment B: 400 mg of pacritinib FMI, PAC400mg FMI
CTI BioPharma, Covance
Healthy
09/15
09/15
NCT02323607: Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Completed
1
13
US
Pacritinib, Oral JAK2 Inhibitor SB1518, SB1518, Cytarabine, CHX-3311, U-19920, Daunorubicin Hydrochloride, DNM, DNR, DRB, Decitabine, 5AZA, DAC, Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies
Bhavana Bhatnagar, CTI BioPharma
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
07/18
07/18
NCT02564536: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Withdrawn
1
0
NA
Pacritinib, Decitabine
Washington University School of Medicine, CTI BioPharma
Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes, Myelofibrosis
06/20
06/20
NCT05657613: Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Completed
1
60
US
CYP450 Cocktail and Transporter Substrates with Pacritinib, Vonjo, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
CTI BioPharma, PPD
Drug Interactions
09/23
12/23
NCT05552183: Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Recruiting
1
32
US
oral dose of 200 mg pacritinib twice daily (BID)
CTI BioPharma, PPD
Hepatic Impairment
05/24
05/24

Download Options